Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RXi Pharmaceuticals Awarded NCI SBIR Funding

Published: Friday, October 12, 2012
Last Updated: Friday, October 12, 2012
Bookmark and Share
Company awarded approximately $300,000 to advance self-delivering RNAi technology.

RXi Pharmaceuticals Corporation has announced that it was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

The grant provides funding for a project enabling the discovery and preclinical development of sd-rxRNAs® as potential therapy for retinoblastoma, a pediatric ocular malignancy.

The project will be completed in collaboration with Dr. David Cobrinik and colleagues at the Memorial Sloan-Kettering Cancer Center.

Dr. Cobrinik commented, "Prior studies performed by RXi and their collaborators at the University of Massachusetts, demonstrated that self-delivering sd-rxRNAs can penetrate the retina and regulate retinal gene expression. As retinoblastomas form within the retina, we hypothesized that sd-rxRNAs might also regulate gene expression in intraocular retinoblastoma cells. This SBIR award will enable us to test this hypothesis, possibly extending the application of sd-rxRNAs from ophthalmic diseases to the cancer setting."

RXi has been awarded approximately $300,000 to fund the collaborative project over six months.

Under this grant (R43CA165899), entitled "Development of sd-rxRNAs® as Therapy for Retinoblastoma and Other Malignancies", sd-rxRNA compounds will be developed to silence one or more targets critical to retinoblastoma cell growth and survival.

The sd-rxRNA compounds will be evaluated for efficacy in in vivo models of retinoblastoma by the Cobrinik lab.

"We are honored to have the opportunity to collaborate with the team at Memorial Sloan-Kettering, and are very pleased to have received financial support from the NCI to further the development of our novel RNAi compounds as potential therapeutics for ocular cancer," said Pamela Pavco, Chief Development Officer at RXi Pharmaceuticals.

Pavco continued, "The grant process is highly competitive, and this award serves to recognize and support the therapeutic potential of RXI's proprietary RNAi platform."

The Small Business Innovation Research (SBIR) program was created by the U.S. Congress to strengthen the role of small, innovative companies in federally supported research and development.

It is one of the largest sources of early-stage technology financing in the U.S. At the National Cancer Institute (NCI), these programs seek small business participation in the development and commercialization of technologies for the treatment and diagnosis of cancer.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising New Data on Self-delivering RNAi Compounds
RXi Pharmaceuticals Corporation have presented new data, on the company's proprietary self-delivering RNAi compounds developed to target Tyrosinase (TYR) and Collagenase (MMP1).
Wednesday, May 13, 2015
RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone™
Samcyprone™ for the treatment of malignant melanoma Stage IIb to IV.
Friday, April 24, 2015
RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement
Agreement for RXI-109 in the European Union under the “Specials” Provision.
Tuesday, November 19, 2013
RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors
Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
Tuesday, April 23, 2013
RXi Pharmaceuticals Completes Apthera Acquisition
The acquisition provides RXi with a late stage product candidate, NeuVax™, a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, patients who are not eligible for Herceptin® RXi has targeted NeuVax to enter Phase III clinical trials in the first half of 2012.
Friday, May 13, 2011
RXi and miRagen Announce Formation of Research Collaboration in the Field of microRNAs
The collaboration will evaluate the potential utility of RXi’s rxRNA™ technology against specific miRNA targets of interest to mirage.
Tuesday, April 13, 2010
RXi Acquires Exclusive License to Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC
The in-licensed technologies encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics.
Wednesday, July 29, 2009
RXi Pharmaceuticals Presented Breakthrough RNAi Delivery Technologies at the TIDES® 2009 Conference
Company’s CSO, Anastasia Khvorova, presented new pre-clinical data on therapeutically advanced RNAi compounds and delivery technologies.
Monday, May 25, 2009
RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
Company plans to advance the discovery and development Oral rxRNA™ therapeutics for inflammatory diseases.
Wednesday, February 11, 2009
RXi Pharmaceuticals Licenses RNA Chemistry Technologies from TriLink Biotechnologies
The agreement includes rights to sublicense a patented RNA linker technology, a patent application on RNAi compositions and an undisclosed chemistry approach.
Tuesday, September 11, 2007
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!